Table 1 Baseline characteristics
First screening | Later screening | Interval cancer | Total | |||||
|---|---|---|---|---|---|---|---|---|
Number 1 251 (20%) | Number 3 849 (60%) | Number 1 287 (20%) | Number 6 387 (100%) | |||||
Median follow-up time 8.5 years | Median follow-up time 5.6 years | Median follow-up time 5.6 years | Median follow-up time 6.0 years | |||||
Number (proportion) | Proportion undergoing BCT | Number (proportion) | Proportion undergoing BCT | Number (proportion) | Proportion undergoing BCT | Number (proportion) | Proportion undergoing BCT | |
BCT | 858 | 69% | 2 844 | 74% | 747 | 58% | 4 449 | 70% |
Median size of tumor | 14.2 mm | 13.5 mm | 18.9 mm | 14.7 mm | ||||
BCT | 13.3 mm | 12.5 mm | 16.9 mm | 13.4 mm | ||||
MTX | 16.1 mm | 16.2 mm | 21.7 mm | 17.7 mm | ||||
Stages | ||||||||
T1N0M0 | 983 (72%) | 71% | 2 868 (75%) | 80% | 637 (49%) | 70% | 4 408 (69%) | 76% |
T2N0M0 | 102 (8%) | 53% | 323 (8%) | 51% | 282 (22%) | 46% | 707 (11%) | 50% |
T1N1M0 | 176 (14%) | 73% | 476 (12%) | 65% | 205 (16%) | 55% | 857 (13%) | 64% |
T2N1M0 | 70 (6%) | 50% | 182 (5%) | 48% | 163 (3%) | 36% | 415 (7%) | 44% |
Tumor status | ||||||||
T1 | 1 079 (86%) | 71% | 3 344 (87%) | 77% | 842 (65%) | 66% | 5 265 (82%) | 74% |
T2 | 172 (14%) | 52% | 505 (13%) | 50% | 445 (35%) | 43% | 1 122 (18%) | 47% |
Nodal status | ||||||||
Negative | 1 005 (80%) | 69% | 3 191 (83%) | 77% | 919 (71%) | 63% | 5 115 (80%) | 73% |
1 node positive | 156 (12%) | 68% | 469 (12%) | 65% | 219 (17%) | 54% | 844 (13%) | 63% |
2 nodes positive | 63 (5%) | 67% | 127 (3%) | 52% | 87 (7%) | 39% | 277 (4%) | 51% |
3 nodes positive | 27 (2%) | 56% | 62 (2%) | 44% | 62 (5%) | 31% | 151 (2%) | 40% |
Histology | ||||||||
Ductal car. | 1 030 (82%) | 70% | 3 136 (81%) | 74% | 1 020 (79%) | 60% | 5 186 (81%) | 71% |
Lobular car. | 117 (9%) | 56% | 360 (9%) | 65% | 145 (11%) | 48% | 622 (10%) | 59% |
Other | 104 (8%) | 70% | 353 (9%) | 78% | 122 (9%) | 53% | 579 (9%) | 72% |
Grade | ||||||||
Grade1 | 472 (35%) | 75% | 1 347 (32%) | 82% | 278 (19%) | 63% | 2 097 (33%) | 78% |
Grade2 | 589 (44%) | 69% | 1 871 (46%) | 72% | 584 (44%) | 61% | 3 044 (48%) | 69% |
Grade3 | 161 (13%) | 52% | 567 (15%) | 65% | 411 (30%) | 52% | 1 139 (18%) | 58% |
Unknown grade | 29 (9%) | 45% | 65 (7%) | 56% | 14 (7%) | 21% | 107 (2%) | 48% |
Hormone status | ||||||||
Positive | 1 119 (89%) | 70% | 3 352 (87%) | 75% | 978 (76%) | 60% | 5 449 (85%) | 71% |
Intermediate | 44 (4%) | 57% | 110 (3%) | 76% | 213 (5%) | 51% | 213 (3%) | 65% |
Negative | 88 (7%) | 60% | 387 (10%) | 62% | 725 (19%) | 51% | 725 (11%) | 58% |